This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
09/03/15 - 3:18:53 PM ET (BATS BZX Real-time Price)
Div Yield: --
ALIM Day's Range
ALIM 52 Week Range
ALIM Business Summary
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company focuses on diseases affecting the back of the eye or retina.View ALIM key stats
Alimera Sciences Inc - ALIM - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Alimera Sciences Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate ALIMERA SCIENCES INC (ALIM) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and generally disappointing historical performance in the stock itself.